Cancer Conference Update

Dr Matthew Galsky discusses recent updates from ASCO 2023 on the management of urothelial bladder cancer moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications here

Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications [here

Dr Elizabeth Plimack from Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses available and emerging therapies for patients with urothelial bladder cancer. CME information and select publications here

Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications here.

Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma. CME information and select publications here

Dr Brian Van Tine discusses new and future research in the management of soft tissue sarcoma and related connective tissue disorders. CME information and select publications here

Dr Jacob Laubach from the Dana-Farber Cancer Institute discusses key presentations in multiple myeloma from the 2022 ASH Annual Meeting. CME information and select publications here.

Dr John Allan from Weill Cornell Medicine in New York City discusses the most important chronic lymphocytic leukemia studies presented at ASH 2022. CME information and select publications here.

Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses the most important lymphoma studies presented at the 2022 ASH Annual Meeting. CME information and select publications here.

Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York City discusses the management of desmoid tumors. CME information and select publications here.

Dr Bob Li from Memorial Sloan Kettering Cancer Center in New York City discusses the current and future roles of targeted therapy for HER2-altered non-small cell lung cancer. CME information and select publications here.

Dr Edward Garon from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, discusses the management of NSCLC in patients who do not have actionable activating mutations. CME information and select publications here.

Dr Srdan Verstovsek from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses new data with myeloproliferative neoplasms presented at the 2022 ASH Annual Meeting. CME information and select publications here.

Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York City discusses recent data from clinical trials evaluating targeted therapies for diffuse large B-cell lymphoma. CME information and select publications here.

Dr Richard Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses new data in acute myeloid leukemia and myelodysplastic syndromes presented at the 2022 ASH Annual Meeting. CME information and select publications here.

Dr Erica Mayer from the Dana-Farber Cancer Institute in Boston, Massachusetts and Dr Ruth O'Regan from the University of Rochester in Rochester, New York discuss new developments in ER-positive breast cancer. CME information and select publications here.

Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy discusses recent therapeutic advances in HER2-positive metastatic breast cancer. CME information and select publications here.

Dr Manish Shah from Weill Cornell Medicine in New York City discusses current approaches to the management of upper GI malignancies and the potential future role of novel therapies for patients with these cancers.  CME information and select publications here.

Dr Scott Tagawa from Weill Cornell Medicine Sandra and Edward Meyer Cancer Center in New York, New York discusses current treatments and management strategies for metastatic urothelial bladder cancer. CME information and select publications here.